ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

PA Center To Receive Share Of State’s Tobacco Settlement.

September 7, 2001

Groups Urge Congress To Enact NIH Budget Increase; Encourage Individual Letters

November 3, 1995

In Brief: Huntsman Cancer Institute Joins NCCN: Howard cancer Center To Honor Mandela

November 7, 1997

Mass. Law Requires Reimbursement For Off-Label Cancer Drugs

January 22, 1993

Melanoma Cancer Vaccine Tested By Cooperative Group

August 29, 2003

The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken.

May 7, 2004